08:33 AM EST, 11/21/2024 (MT Newswires) -- Conduit Pharmaceuticals ( CDT ) said Thursday that the Japan Patent Office has approved a composition of matter patent for the company's lead asset, AZD1656, which is a glucokinase activator that targets various autoimmune disorders.

The company said the approval follows a recent patent grant in Australia.